Skip to content

About us
- Mission
- Strategy
- Our story
- Our team
Inobrodib
- Science
- Publications
Clinical trials
- Indications under investigation
- Current clinical trials
News
- Press releases
Contact us

About us
- Mission
- Strategy
- Our story
- Our team
Inobrodib
- Science
- Publications
Clinical trials
- Indications under investigation
- Current clinical trials
News
- Press releases
Contact us

AACR, Atlanta, Elvin (2019)

p300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumour AR and c-Myc gene expression in vivo.

Applications

Inobrodib is currently being evaluated for safety and effectiveness in multiple specific settings

Haematological Malignancies

Blood cancers including multiple myeloma, acute myeloid leukaemia, myelodysplastic syndrome and T Cell lymphomas

Solid Tumours

Metastatic castrate-resistant prostate cancer (mCRPC) and other targeted tumours.

About CellCentric

CellCentric is a clinical stage biotech company focused on the development of a first of its kind, p300/CBP inhibitor to treat specific cancer types.

Quick Links

About us
Inobrodib
Clinical trials
Publications
Our story

Menu

About us
Inobrodib
Clinical trials
Publications
Our story

Our team
Press releases
News
Contact
Expanded Access Policy

Menu

Our team
Press releases
News
Contact
Expanded Access Policy

Follow us

Follow us and stay up to date with our latest news, events and scientific posters.

Twitter Linkedin-in

© CellCentric Limited 2023 | Company #4948632

Designed and built by OSM Group

Main Menu

About us
- Mission
- Strategy
- Our story
- Our team
Inobrodib
- Science
- Publications
Clinical trials
- Indications under investigation
- Current clinical trials
News
- Press releases
Contact us

Follow us on Twitter